The Global Health Body Sounds Concern Over Critical Lack of Obesity Jabs
Under a tenth of patients who could benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it issues its inaugural advice on the medications.
Considering more than one billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
According to forecasts, over two billion could be obese by 2030 if no action is taken.
"The new guidance affirms that excess weight is a long-term condition that can be addressed with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major barriers to universal availability to the jabs that can assist patients in reducing considerable weight, says the agency.
Skinny Jab Scarcity
Despite the current most optimistic case, the supply of GLP-1 therapies could only cover around 100 million people – under 10% of those who need them, per the health organization.
The guideline urges nations and manufacturers to increase availability, via approaches including patent sharing.
Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Weight-Loss Injections Function
The injections replicate a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so users reduce food intake.
Individuals usually begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Studies points to patients may put most of the weight back on within a year of discontinuing the medication, when their normal hunger come back.
To be carrying excess weight elevates your likelihood for developing health problems, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight impacts individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
